Akari Therapeutics develops antibody-drug conjugates with PH1, a payload designed to disrupt RNA splicing in cancer cells and activate immune responses.
Akari Therapeutics develops antibody-drug conjugates with PH1, a payload designed to disrupt RNA splicing in cancer cells and activate immune responses.